OSIC is an effort between academia, industry & patient advocacy to enable rapid advances against IPF and other ILDs using machine learning. Global, 501(c)(3)
๐๐ฎ๐ฌ๐ญ ๐จ๐ฎ๐ญ: ๐ ๐ง๐๐ฐ ๐๐ฉ๐ฉ๐ซ๐จ๐๐๐ก ๐ญ๐จ ๐ข๐๐๐ง๐ญ๐ข๐๐ฒ๐ข๐ง๐ ๐๐๐ซ๐ฅ๐ฒ ๐๐ข๐๐ซ๐จ๐ญ๐ข๐ ๐ฅ๐ฎ๐ง๐ ๐๐ข๐ฌ๐๐๐ฌ๐ ๐ข๐ง ๐ฅ๐ฎ๐ง๐ ๐๐๐ง๐๐๐ซ ๐ฌ๐๐ซ๐๐๐ง๐ข๐ง๐ .
Expanded detection of early fibrotic phenotypes using lobar traction bronchiolectasis in lung cancer screening
๐๐ณ๐ฆ ๐ค๐ถ๐ณ๐ณ๐ฆ๐ฏ๐ต ๐ค๐ญ๐ข๐ด๐ด๐ช๐ง๐ช๐ค๐ข๐ต๐ช๐ฐ๐ฏ ๐ด๐บ๐ด๐ต๐ฆ๐ฎ๐ด ๐ถ๐ฏ๐ฅ๐ฆ๐ณ๐ฆ๐ด๐ต๐ช๐ฎ๐ข๐ต๐ช๐ฏ๐จ ๐ค๐ญ๐ช๐ฏ๐ช๐ค๐ข๐ญ๐ญ๐บ ๐ฎ๐ฆ๐ข๐ฏ๐ช๐ฏ๐จ๐ง๐ถ๐ญ ๐ฅ๐ช๐ด๐ฆ๐ข๐ด๐ฆโ๐ข๐ฏ๐ฅ ๐ฎ๐ช๐ด๐ด๐ช๐ฏ๐จ ๐ต๐ฉ๐ฆ ๐ธ๐ช๐ฏ๐ฅ๐ฐ๐ธ ๐ง๐ฐ๐ณ ๐ฆ๐ข๐ณ๐ญ๐บ ๐ฅ๐ฆ๐ต๐ฆ๐ค๐ต๐ช๐ฐ๐ฏ ๐ฐ๐ง ๐ข๐ฏ ๐๐๐? ๐๐๐๐จ ๐จ๐ฉ๐ช๐๐ฎ ๐จ๐ช๐๐๐๐จ๐ฉ๐จ ๐ฉ๐๐ ๐๐ฃ๐จ๐ฌ๐๐ง ๐ข๐๐ฎ ๐๐ ๐ฎ๐๐จ.
By focusing on traction bronchiolectasis as an early imaging marker of fibrosis, the proposed approach identifies substantially more patients with undiagnosed fibrotic ILD.
As lung cancer screening continues to scale, incidental interstitial findings will only become more common. The field will need imaging frameworks that are not only sensitive, but also reproducible and clinically meaningful.
Congratulations to all of the authors on this important contribution, including OSICโs UK-based radiology lead, Prof. Joseph Jacob, @UCL Centrefor Medical Image Computing (CMIC)!
https://t.co/WTm3gIkgAb
#ILD #PulmonaryFibrosis #LungCancerScreening #ThoracicImaging #Radiology #Pulmonology #ClinicalResearch #EarlyDetection #Pharma #MedTech #OSICILD
๐๐ก๐ ๐๐ฎ๐ง๐ ๐๐๐ ๐๐จ๐๐๐๐ฌ๐ญ
25 ๐๐๐๐๐ ๐๐ ๐๐ข๐๐๐๐๐๐๐๐๐ฆ: ๐ท๐. ๐ฟ๐๐ ๐ ๐ฟ๐๐๐๐๐ ๐ก๐๐ ๐๐ ๐โ๐ ๐ฟ๐๐๐ ๐ ๐๐๐ ๐ก๐ ๐ท๐๐๐๐๐๐ ๐๐
In this insightful episode, Dr. Lisa LancasterโChief Medical Officer at @EndeavorBioMed and Interstitial Lung Disease Program Director at @VUMCDiscoveries โjoins Elizabeth Estes to reflect on 25 years in pulmonology and the challenges patients face on the path to diagnosis. From missed signs to delayed answers, they explore whatโs changingโand what still needs to improve.
This conversation offers perspective, progress, and hope for a future where pulmonary fibrosis is caught earlier and treated more effectively.
#PulmonaryFibrosis #Pulmonology #LungHealth #RareDisease #HealthcareInnovation #PrecisionMedicine #OSICILD
Next on The Lung Lab: Dr. Lisa LancasterโILD leader and Chief Medical Officerโpulls back the curtain on the long road to diagnosis, the reality of delivering life-changing news, and where real breakthroughs in ILD are finally taking shape.
https://t.co/TJioWXafsL
@OSICild
๐๐โ๐ซ๐ ๐ก๐จ๐ง๐จ๐ซ๐๐ ๐ญ๐จ ๐ฌ๐ก๐๐ซ๐ ๐ญ๐ก๐๐ญ ๐ญ๐ก๐ ๐๐ฉ๐๐ง ๐๐จ๐ฎ๐ซ๐๐ ๐๐ฆ๐๐ ๐ข๐ง๐ ๐๐จ๐ง๐ฌ๐จ๐ซ๐ญ๐ข๐ฎ๐ฆ (๐๐๐๐) ๐ก๐๐ฌ ๐๐๐๐ง ๐ง๐๐ฆ๐๐ ๐ ๐๐ข๐ง๐๐ฅ๐ข๐ฌ๐ญ ๐๐จ๐ซ ๐ญ๐ก๐ ๐ ๐ข๐๐ซ๐๐ ๐๐ข๐จ๐ญ๐๐๐ก ๐๐ฎ๐ญ๐ฌ๐ญ๐๐ง๐๐ข๐ง๐ ๐๐ฐ๐๐ซ๐๐ฌ.
OSIC was built to solve a problem. In rare lung disease, data were fragmented, inconsistent, and difficult to use at scale. And although progress has been made, it feels slower than it should be.
So we chose a path rooted in collaboration, shared governance, and learning openly from both successes and failures, with the belief that better infrastructure can unlock better science.
What has emerged is more than a database, itโs a growing intelligence platform that helps turn imaging and clinical data into something structured, reproducible, and usable for real progress in drug development.
But the reason we do this has never changed....It is for the patients, families, and caregivers who do not have time to wait for the system to catch up. We are committed to radical progress for them!
We are deeply grateful to the global community of investigators, partners, and contributors who have built this with us. And we are honored to be recognized alongside others working to push what is possible in biotech.
Meet the Fierce Outsourcing Awards 2026 Finalists! https://t.co/wKIb1T3ZKx
#OSICILD
๐๐ก๐ ๐๐ฎ๐ง๐ ๐๐๐ โ ๐ ๐ง๐๐ฐ ๐ฉ๐จ๐๐๐๐ฌ๐ญ ๐๐ซ๐จ๐ฆ ๐๐๐๐.
Exploring whatโs next in rare lung disease.
For patients. For families. For progress.
Elizabeth Estes
Radiologists arenโt working alone anymoreโphysicians, patients, caregivers, and machine experts are shaping the story of rare and fibrotic lung diseases.
Go behind the scenes of @OSICild The Lung Lab.
https://t.co/YdCNSFcAal
๐๐ง๐ญ๐ซ๐จ๐๐ฎ๐๐ข๐ง๐ ๐๐ก๐ ๐๐ฎ๐ง๐ ๐๐๐ โ ๐ ๐ง๐๐ฐ ๐ฉ๐จ๐๐๐๐ฌ๐ญ ๐๐ซ๐จ๐ฆ ๐ญ๐ก๐ ๐๐ฉ๐๐ง ๐๐จ๐ฎ๐ซ๐๐ ๐๐ฆ๐๐ ๐ข๐ง๐ ๐๐จ๐ง๐ฌ๐จ๐ซ๐ญ๐ข๐ฎ๐ฆ (๐๐๐๐). Over the past several years, OSIC has worked alongside researchers, clinicians, and patients across the rare lung disease community. Along the way, weโve seen both meaningful progress and the real challenges that still remain.
๐๐ก๐ ๐๐ฎ๐ง๐ ๐๐๐ is a space to explore those realities. Each episode looks at how rare and progressive lung diseases are being understood today and where things may be heading next, from earlier detection to new approaches in treatment.
The goal is simple: to bring together the people and ideas shaping what comes next, and to make that conversation more accessible. This work is grounded in something biggerโฆ.the need to make real, and hopefully, radical progress on behalf of patients, caregivers, and families who are living with these diseases every day.
In our first episode, OSICโs Executive Director, Elizabeth Estes, shares ๐พ๐๐๐ ๐ฐ๐ ๐พ๐ ๐ช๐๐๐๐ ?โ๐๐๐ ๐๐๐๐๐ ๐๐๐๐๐๐ ๐๐๐ ๐ ๐๐๐๐๐๐๐๐๐๐ ๐๐ ๐ ๐๐๐๐๐๐ ๐๐๐๐ ๐๐๐๐๐๐๐ ๐๐๐ ๐๐๐๐๐๐๐๐ ๐ ๐๐๐๐๐๐, ๐๐๐ ๐๐๐๐ ๐๐ ๐๐๐๐๐ ๐๐๐๐ ๐๐๐๐๐๐๐๐.
New episodes will be released every other week over the next three months, featuring voices from across research, medicine, and technology. ๐๐๐ฑ๐ญ ๐ฎ๐ฉ: ๐๐ซ. Lisa Lancaster, Chief Medical Officer at @EndeavorBioMed and Interstitial Lung Disease Program Director at @VUMCDiscoveries.
https://t.co/STGu3U4viQ
#TheLungLab #OSICILD #LungHealth #Podcast #LungDisease
๐ Congratulations on the excellent @Nature article, @OSICild! We are encouraged by the progress, and proud to play a role in pursuing your mission in #ILD.
https://t.co/te3PyEB8aT
Thanks to Neil Savage and @naturemagazine for this article that explores recent advancements aimed at improving the diagnosis and treatment of lung diseases, and highlights how data from our repository is helping researchers better understand #IPF and deliver more accurate prognoses.
With #AI enhancing imaging analysis, earlier detection and better monitoring of disease progression are becoming possible. Enhanced screening and AI-driven assessments are paving the way for more personalized treatments.
Together, these innovations offer hope for earlier intervention, improved patient management, and a better understanding of lung diseases. Weโre proud to be advancing #ILD and rare lung disease research, driving breakthroughs that bring hope to patients worldwide.
https://t.co/GG8b0VMQP3
May this coming year bring you healthy days, happy weeks, and countless opportunities for growth and innovation.
We're excited to see all the great things we'll accomplish together in the months ahead!
HAPPY NEW YEAR!
New Frontiers for Progress: Catalyzing Breakthroughs in Lung Disease
OSICโs Annual Member Meeting is coming to Amsterdam! Join us on September 27 for an afternoon of discovery:
- Bronchiectasis: The Next Therapeutic Frontier โ How imaging, phenotyping, and AI are redefining this once-overlooked condition. Dr. Kevin Brown, Dr. Helmut Prosch, Dr. Luca Richeldi.
- Sarcoidosis: From Complexity to Clarity โ With Elise Hoover (Foundation For Research @StopSarcoidosis ), unveiling global registry efforts and AI collaborations.
- Generative AI in Action โ Featuring Dr. David Barber (@ucl ), showing how AI can predict disease progression earlier and build cross-disease models.
- OCT Imaging Spotlight โ Dr. Lida Hariri on in vivo lung microstructure, the โvirtual biopsyโ of fibrosis.
- Exploring New Features and Advanced Filters inย the OSIC Cloud โ Sandra Stapleton (VIDA).
- Member Success Stories โ See how leading companies like @CorelineSoft , GMV, @ThisIsThirona , and @Brainomix are using OSIC data to accelerate innovation.
Donโt miss this chance to see how OSIC is turning data into discovery.
#AIinHealthcare #LungDisease #Bronchiectasis #Sarcoidosis #GenerativeAI #MedicalImaging #DigitalHealth #RareDisease #ClinicalAI #OSICILD #CollaborationForCure #ERS2025
See full agenda and meeting details:
https://t.co/ReGVp8UL7G
September is Pulmonary Fibrosis Awareness Month, a time to bring attention and support to the thousands of patients and caregivers around the world living with this chronic โ and incurable โ lung disease.
At OSIC, we are passionately committed to making radical progress for those living with #PF and other #ILDs.ย Through the power of collaboration and innovation, we know we can get there. Thank to you all of our partners for their commitment to our mission.
Join us in raising awareness this September. Together, we can accelerate research, enhance treatment, and improve lives.
#PFMonth #CurePF #PulmonaryFibrosisAwareness #ILD
Weโre headed to Boston next week for the 9thย Annual IPF Summit!
If youโre attending, please join us on Thursday, August 21 at 8:30 a.m. ET for our seminar, โThe Canary, the Code, and ILAs: Generative AI, a Video Game, and the Future of Lung Disease.โ
Our Executive Director Elizabeth Estes @eec1968 will discuss what Generative AI looks like in lung disease, and how OSIC is rethinking traditional research models by using a video game to engage diverse contributors in annotating ILAs and advancing early detection.
And please reach out if youโll be in town โ weโd love to meet up!
Learn more about the session: https://t.co/qem5pE92wY
#IPFSummit #OSICild #IPF #ILD